MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jad.2019.10.040

Медицинская библиотека · Journal of affective disorders · 2019

Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.

Sakurai Hitoshi, L Carpenter Linda, R Tyrka Audrey, Price Lawrence H, I Papakostas George, Dording Christina M, Yeung Albert S, Cusin Cristina, Ludington Elizabeth, Bernard-Negron Richard, Fava Maurizio, Mischoulon David

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

The optimal dose of S-adenosyl methionine (SAMe) for major depressive disorder (MDD) remains unclear. The objective of this analysis was to address whether a dose increase provided further improvement in cases of insufficient response using data from an existing randomized clinical trial.

METHODS

Sixty-five patients with MDD who failed to respond to SAMe 1,600 mg/day, escitalopram 10 mg/day, or placebo for 6 weeks were treated with doubled doses of the allocated treatments for the following 6 weeks. Changes in 17-item Hamilton Depression Rating Scale, Inventory of Depressive Symptomatology-Self Rated, and Systematic Assessment for Treatment Emergent Events-Specific Inquiry were compared between the lower and higher dose treatments in each treatment group and among the higher dose treatments of SAMe, escitalopram, and placebo.

RESULTS

Various depression severity scores decreased significantly for all three treatment arms during the higher dose treatment. No within-group and between-group differences were found in any of the efficacy measures when comparing the doses and treatments. There was a significant difference in reported abdominal discomfort among patients receiving the higher dose of SAMe (31.3%), compared to escitalopram (8.7%) and placebo (3.8%) (χ2=7.32, p = 0.026).

LIMITATIONS: The sample size was relatively small. The study duration for dose increase was relatively short.

CONCLUSIONS

Patients with MDD failing to respond to 1,600 mg/day of SAMe may improve after increasing the dose to 3,200 mg/day, but we cannot rule out the contribution of a placebo effect and time-related improvement. The risk of abdominal discomfort may be increased with higher doses of SAMe.

Для цитирования: Sakurai Hitoshi, L Carpenter Linda, R Tyrka Audrey, Price Lawrence H, I Papakostas George, Dording Christina M, Yeung Albert S, Cusin Cristina, Ludington Elizabeth, Bernard-Negron Richard, Fava Maurizio, Mischoulon David. Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.. Journal of affective disorders. 2019. DOI: 10.1016/j.jad.2019.10.040.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.